Scrip“Either for young biotech or established pharma companies in China, a combination of innovation and globalization is the trend,” Shan Jiang, chief technology officer at Hansoh Pharmaceutical, told the
ScripThe Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month. T
ScripFor Chinese pharma companies, betting even a sliver of their total research and development spendings on original innovation can make a difference. That very difference may determine whether they can
ScripBioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou